STORM Therapeutics announces closing of USD $30M Series B financing.
14 December, 2022. Cambridge, England. STORM Therapeutics Ltd. (STORM), the clinical biotechnology company discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases, today announced the successful completion of a USD $30 million Series B financing round. The financing was co-led by existing investors M Ventures, Pfizer […]
STORM Therapeutics announces closing of USD $30M Series B financing. Read More »